# Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

> **NCT00580333** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 51 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** bevacizumab
- **DRUG:** doxorubicin
- **DRUG:** cyclophosphamide
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00580333
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-12
- **Final completion:** 2020-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2021-05-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00580333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00580333, "Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00580333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*